Dacabavir is a hepatitis C virus (HCV) NS5A inhibitor suitable for use in the treatment of chronic HCV genotype 3 infection with sofosbuvir [sofosbuvir].
Dosage and method of administration
2.1 Recommended dose
The recommended dose of dactavir is 60 mg, orally, once a day for 12 weeks with sofosbuvir. Dacartamine can be taken with or without food.
The best time to treat patients with sclerosing dakotavir and sofosbuvir has not been determined [see Clinical Studies (14)].
For specific recommended doses of sofosbuvir, refer to the relevant prescription materials.
2.2 due to drug interaction dose modification
Reference to drug interactions and contraindications for other drugs prior to co-administration with dacarevir.
Cytochrome P450 Enzyme 3A (a strong inhibitor of CYP3A: reduce the dose of daclitaxel to 30 mg once daily using a 30 mg tablet when co-administered with a strong CYP3A inhibitor [see Drug Interactions (7)].
Moderate CYP3A inducer: when co-administered with a moderate CYP3A inducer to increase the dose of daclitaxel to 90 mg once daily using the appropriate combination of tablets (three 30 mg tablets or one piece 60 mg and one 30 mg tablet) [See Drug Interactions (7)].
Strong CYP3A inducer: Dacarevir is contraindicated in combination with a strong CYP3A inducer [see Contraindications (4)].
Adverse reactions are not recommended to reduce the dose of daclitaxel.
2.3 Termination of treatment
One patient who received d'Acyclovir and sofosbuvir discontinued sofosbuvir permanently, and then dacarevir should also be discontinued.
Cool,dry and hermetic place